Significant evidence supports the use of xanthine oxidase inhibitors (allopurinol, febuxostat) for management of hyperuricemia, SGLT2 inhibitors for control of glucose, and statins for dyslipidemia, and nephrologists therefore have specific pharmacological tools that target the metabolic pathways which drive CKD progression. Here, SLC5A2 is linked to metabolic syndrome.